Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review

A temporary discontinuation (drug holiday) of high-dose antiresorptive (AR) agents has been proposed to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ). The aim of this systematic review was to answer the question: Is high-dose AR drug holiday, at the time of tooth extraction...

Full description

Bibliographic Details
Main Authors: Camilla Ottesen, Morten Schiodt, Klaus Gotfredsen
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402030640X
id doaj-feab5323f53049dcb30b1426aab945ab
record_format Article
spelling doaj-feab5323f53049dcb30b1426aab945ab2020-11-25T03:34:09ZengElsevierHeliyon2405-84402020-04-0164e03795Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic reviewCamilla Ottesen0Morten Schiodt1Klaus Gotfredsen2Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; Department of Oral & Maxillofacial Surgery, Copenhagen University Hospital, Denmark; Corresponding author.Department of Oral & Maxillofacial Surgery, Copenhagen University Hospital, Denmark; Department of Clinical Epidemiology, Aarhus University Hospital, DenmarkDepartment of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, DenmarkA temporary discontinuation (drug holiday) of high-dose antiresorptive (AR) agents has been proposed to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ). The aim of this systematic review was to answer the question: Is high-dose AR drug holiday, at the time of tooth extraction or dentoalveolar surgery, necessary to prevent the development of MRONJ in patients with cancer? This protocol was registered in the PROSPERO database. Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for relevant studies up to and including April 2019. Randomized controlled trials (RCTs), cohort and cross-sectional studies, surveys, and case reports with more than five patients were included. Records were imported into www.covidence.org. Electronic searches were supplemented by manual searches and reference linkage. The Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) were followed. Although only one study fitted the population, intervention, comparison, outcome (PICO) framework, valuable information on AR drug holiday could be extracted from 14 of 371 reviewed articles. Among these, 3 were prospective and 11 were retrospective studies. These studies described or evaluated high-dose AR drug holidays. In 2 studies, patients were being treated with denosumab, but neither showed that a drug holiday was effective. The remaining 12 studies evaluated bisphosphonate treatment and 2 of these studies found no reason to use AR drug holiday before surgery. Three studies recommended drug holidays, whereas most of the studies recommended assessing each patient separately. The only paper that fitted the PICO approach was a non-randomized, prospective study with a control group. This study concluded that drug holiday was not necessary. Thus, there are no evidence for using drug holiday, but it is also clear that caused by a limited numbers of eligible patients, and a great variation in between these patient, high-level evidence for using AR drug holiday is almost impossible to obtain.http://www.sciencedirect.com/science/article/pii/S240584402030640XCancer surgeryClinical researchDental surgeryDentistryOral medicinePharmacology
collection DOAJ
language English
format Article
sources DOAJ
author Camilla Ottesen
Morten Schiodt
Klaus Gotfredsen
spellingShingle Camilla Ottesen
Morten Schiodt
Klaus Gotfredsen
Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
Heliyon
Cancer surgery
Clinical research
Dental surgery
Dentistry
Oral medicine
Pharmacology
author_facet Camilla Ottesen
Morten Schiodt
Klaus Gotfredsen
author_sort Camilla Ottesen
title Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
title_short Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
title_full Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
title_fullStr Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
title_full_unstemmed Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
title_sort efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (mronj): a systematic review
publisher Elsevier
series Heliyon
issn 2405-8440
publishDate 2020-04-01
description A temporary discontinuation (drug holiday) of high-dose antiresorptive (AR) agents has been proposed to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ). The aim of this systematic review was to answer the question: Is high-dose AR drug holiday, at the time of tooth extraction or dentoalveolar surgery, necessary to prevent the development of MRONJ in patients with cancer? This protocol was registered in the PROSPERO database. Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for relevant studies up to and including April 2019. Randomized controlled trials (RCTs), cohort and cross-sectional studies, surveys, and case reports with more than five patients were included. Records were imported into www.covidence.org. Electronic searches were supplemented by manual searches and reference linkage. The Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) were followed. Although only one study fitted the population, intervention, comparison, outcome (PICO) framework, valuable information on AR drug holiday could be extracted from 14 of 371 reviewed articles. Among these, 3 were prospective and 11 were retrospective studies. These studies described or evaluated high-dose AR drug holidays. In 2 studies, patients were being treated with denosumab, but neither showed that a drug holiday was effective. The remaining 12 studies evaluated bisphosphonate treatment and 2 of these studies found no reason to use AR drug holiday before surgery. Three studies recommended drug holidays, whereas most of the studies recommended assessing each patient separately. The only paper that fitted the PICO approach was a non-randomized, prospective study with a control group. This study concluded that drug holiday was not necessary. Thus, there are no evidence for using drug holiday, but it is also clear that caused by a limited numbers of eligible patients, and a great variation in between these patient, high-level evidence for using AR drug holiday is almost impossible to obtain.
topic Cancer surgery
Clinical research
Dental surgery
Dentistry
Oral medicine
Pharmacology
url http://www.sciencedirect.com/science/article/pii/S240584402030640X
work_keys_str_mv AT camillaottesen efficacyofahighdoseantiresorptivedrugholidaytoreducetheriskofmedicationrelatedosteonecrosisofthejawmronjasystematicreview
AT mortenschiodt efficacyofahighdoseantiresorptivedrugholidaytoreducetheriskofmedicationrelatedosteonecrosisofthejawmronjasystematicreview
AT klausgotfredsen efficacyofahighdoseantiresorptivedrugholidaytoreducetheriskofmedicationrelatedosteonecrosisofthejawmronjasystematicreview
_version_ 1724560262908870656